Y mAbs Therapeutics

Y mAbs Therapeutics — Q2 2024 Earnings Presentation

20 slides from Y mAbs Therapeutics's earnings presentation, Aug 12, 2024

  1. Slide 1: Q2 2024 Financial Results and Corporate Update

    Q2 2024 Financial Results and Corporate Update August 12, 2024

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains forward-looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995. The forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this pre

  3. Slide 3: Intro and Company Overview - Mike Rossi

    Mike Rossi President and CEO Intro and Company Overview 3

  4. Slide 4: Agenda

    Agenda Company Overview 1 Mike Rossi, President and Chief Executive Officer DANYELZA Global Sales 2 Sue Smith, Chief Commercial Officer Naxitamab Development Program 3 Vignesh Rajah, Chief Medical Officer Q2 2024 Financials 4 Peter Pfreundschuh, Chief Financial Officer Q&A 5 All 4

  5. Slide 5: DANYELZA Highlights

    DANYELZA Highlights • Q2 2024 total DANYELZA net product revenues of $22.8M,  10% YoY • 1H 2024 total DANYELZA net product revenues of $42.2M,  3% YoY • DANYELZA added to 2 new hospital formularies in the U.S. in Q2 2024 • Remains a leading anti-GD2 therapy in the U.S. • Increased ex-U.S. revenue

  6. Slide 6: GD2-SADA Phase 1 Clinical Trial (Study 1001): Dosing Patients in Part A

    GD2-SADA Phase 1 Clinical Trial (Study 1001): Dosing Patients in Part A Theranostic approach using a 30 mCi 177Lu-DOTA imaging dose before exposing to therapeutic dose Part A* Part B Part C Inclusion Criteria N ≈ 15 – 18 N ≈ 9 – 12 5 cycles 177Lu-DOTA therapeutic • ECOG performance GD2-SADA protein

  7. Slide 7: Ongoing GD2-SADA Phase 1 Clinical Trial (Study 1001): Part A Overview

    Ongoing GD2-SADA Phase 1 Clinical Trial (Study 1001): Part A Overview TRIAL UPDATE PART A DATA ELEMENTS › Solid tumors (SCLC, malignant melanoma, sarcomas) › Completed Cohorts 1 through 4; currently in Cohort 5* • Optimal and safe GD2-SADA protein dose › 17 patients dosed to date* • Dosing interval

  8. Slide 8: CD38-SADA Phase 1 Clinical Trial (Study 1201): Planned Design

    CD38-SADA Phase 1 Clinical Trial (Study 1201): Planned Design Theranostic approach using CD38 positivity on IHC and 177Lu-DOTA organ dosimetry before repeat dosing in patients with relapsed or refractory non-Hodgkin Lymphoma Part A Part B N = 12 – 15 N = 12 – 15 Inclusion Criteria TRIAL UPDATE • R/R

  9. Slide 9: Global DANYELZA Sales - Sue Smith

    Sue Smith Chief Commercial Officer Global DANYELZA Sales 9

  10. Slide 10: Q2 2024 DANYELZA Global Commercial Update

    Q2 2024 DANYELZA Global Commercial Update • Q2 2024 Total DANYELZA net product revenues of $22.8M,  10% YoY • Q2 2024 U.S. DANYELZA net product revenues of $15.2M, 4% YoY • Q2 2024 Ex-U.S. DANYELZA net product revenues of $7.6M,  55% YoY • 65 U.S. accounts* since initial launch; 7 new accounts ad

  11. Slide 11: Naxitamab Development Program - Vignesh Rajah

    Vignesh Rajah Chief Medical Officer Naxitamab Development Program 11

  12. Slide 12: Ongoing Naxitamab Clinical Trials

    Ongoing Naxitamab Clinical Trials • Multi-center Phase 2 trial • Phase 2 BCC multi-center • ISS Phase 1b/2 trial • Randomized Phase 2 trial investigating naxitamab trial evaluating naxitamab investigating TGFβ NKs, evaluating efficacy and in patients with relapsed + standard induction gemcitabine +

  13. Slide 13: Q2 2024 Financials - Peter Pfreundschuh

    Peter Pfreundschuh Chief Financial Officer Q2 2024 Financials 13

  14. Slide 14: Key Q2 2024 and 1H Financial Highlights: Revenue

    Key Q2 2024 and 1H Financial Highlights Revenue Three months ended Jun 30, Six months ended Jun 30, 2024 2023 2024 2023 Net product revenue $22.8 M $20.8 M Net product revenue $42.2 M $41.0 M License revenue – – License revenue $0.5 M – Total revenue $22.8 M $20.8 M Total revenue $42. 7 M $41.0 M Ne

  15. Slide 15: Key Q2 2024 and 1H Financial Highlights: Operating Expenses

    Key Q2 2024 and 1H Financial Highlights Operating Expenses Three months ended Jun 30, Six months ended Jun 30, 2024 2023 2024 2023 Cost of goods sold $3.0 M $4.6 M Cost of goods sold $5.1 M $6.7 M License royalties – – License royalties $0.05 M – Research & development $12.3 M $12.1 M Research & dev

  16. Slide 16: Key Q2 2024 and 1H Financial Highlights: Net Loss

    Key Q2 2024 and 1H Financial Highlights Net Loss Three months ended Jun 30, Six months ended Jun 30, 2024 2023 2024 2023 Net loss $(9.2) M $(6.3) M Net loss $(15.9) M $(12.7) M Net loss per basic, diluted share $(0.21) $(0.14) Net loss per basic, diluted share $(0.36) $(0.29) Net loss Net loss  47%

  17. Slide 17: Key Q2 2024 Financial Highlights

    Key Q2 2024 Financial Highlights Responsible stewards of capital As of Six months ended Jun 30, Jun 30, 2024 Dec 31, 2023 2024 2023 Cash and cash equivalents $77.8 M $78.6 M Cash use $0.8 M $17.9 M Anticipated cash runway Cash use into 2027*  96% YoY *This estimate reflects the Company's current bu

  18. Slide 18: Financial Guidance for Full Year 2024

    Financial Guidance for Full Year 2024 UPDATED $87 million to $95 million Total Net Revenues: REITERATE $115 million to $120 million Total Expected Operating Expenses: REITERATE $15 million to $20 million Total Expected Cash Burn: Cash and cash equivalents anticipated to support operations as current

  19. Slide 19: Q&A

    Q&A Mike Rossi Sue Smith President and Chief Commercial Officer Chief Executive Officer Vignesh Rajah, MBBS, Peter Pfreundschuh DCH, MRCP Chief Financial Officer Chief Medical Officer 19

  20. Slide 20: Thank You

    Thank You

Y-mAbs Therapeutics — Q2 2024 Earnings Presentation on 6ix